Tagitanlimab

塔戈利单抗

Report date: 2026/05/13 20:02:10

Base Information

Drug NameTagitanlimab
Drug Alias NametagolimumabKL-A167注射液泰特利单抗注射液科泰莱KL-A167 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[12] 
Global Approved IndicationsNasopharyngeal Carcinoma
Approved Indications in ChinaNasopharyngeal Carcinoma
Original Approved Country/TerritoryMainland China
Original Approved Date2024/12/25
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSichuan Kelun-Biotech Biopharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHarbour BiomedSun Yat-Sen UniversitySichuan Kelun-Biotech Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[12] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A